Mepolizumab is not inferior to omalizumab, improving asthma control in severe allergic and eosinophilic asthma, a randomised, blinded, non-inferiority trial. - Vienna 2024

Clinical problems in respiratory medicine II

Chair(s): Emad Eldin Ibrahim, Ranjit Kumar Singh

Session type: Poster session

Mepolizumab is not inferior to omalizumab, improving asthma control in severe allergic and eosinophilic asthma, a randomised, blinded, non-inferiority trial.

Peter Wark

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Pulmonary manifestations of antiphospholipid syndrome: a retrospective analysis of 121 patients

Biljana Lazovic

Abstract

Evaluation of normal pre-bronchodilator FEV1/VCMax in the context of significant bronchodilator responsiveness

Dominic Evans

Poster

Abstract

Interstitial lung disease: performance of neutrophil-lymphocyte ratio in predicting progression

Nourchene Khalfallah

Poster

Abstract

Clinical utility of metagenomic next-generation sequencing negative results in corticosteroid-responsive diffuse parenchymal lung diseases

Wenkui Sun

Poster

Abstract

Childhood asthma risk prediction - clinician judgement versus Pediatric Asthma Risk Score as a clinical decision support tool

Arthur Owora

Poster

Abstract

The efficacy and safety of osimertinib in patients with advanced EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled trials

Xiumei Tang

Poster

Abstract

Frequency and severity of asthma in patients with hiatal hernia

Michel Abou Khalil

Poster

Abstract

Differences in the progression among mild, moderate and severe pulmonary fibrosis on HRCT scan in Usual Interstitial Pneumonia (UIP) cohort in the United Arab Emirates (UAE)

Khaled Saleh

Abstract

Prognostic role of novel inflammatory biomarkers in patients with chronic obstructive pulmonary disease with metabolic syndrome

Jamol Uzokov

Poster

Abstract

Correlation of functional data with diaphragm measurements evaluated by ultrasound in patients with Interstitial Lung Disease

Ayseg?l Sahin

Poster

Abstract

Necrostatin-1 can inhibit the necroptosis and improve diaphragm function in the sepsis mice sepsis by cecal ligation and puncture

Xin Fu

Abstract

Asthma, gestational diabetes mellitus and adverse perinatal outcomes: an Australian population-based analysis

Vanessa E. Murphy

Poster

Abstract

Assessment of osteoporosis and fracture risk in people with interstitial lung disease, can we do better?

Laura Chapman

Poster

Abstract

Mepolizumab is not inferior to omalizumab, improving asthma control in severe allergic and eosinophilic asthma, a randomised, blinded, non-inferiority trial.

Peter Wark

Poster

Abstract

Risk factors for respiratory relapses in patients with EGPA

Justyna Fijo?ek

Poster

Abstract

Reducing the environmental impact of asthma and its treatment: findings from the SENTINEL pilot site

Michael Crooks

Poster

Abstract

Granulomatous inflammation in EBUS-FNA negatively predicts malignant nodal involvement in patients with co-existing past or present malignancy.

Ishitha Gunadala

Abstract

Suboptimal response to biologics in severe asthma patients with humoral immunodeficiencies

Angelica Tiotiu Cepuc

Poster

Abstract

Efficacy of dupilumab in patient with hypereosinophilic syndrome and asthma non-responsive to anti-IL5 and anti-IL5r treatment.

Dominika Ochab-krupnik

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}